100042-34-0

Basic information

• Product Name: 2-Propen-1-one,3-(3,4-dihydroxyphenyl)-1-(4-morpholinyl)-, (2E)-
• Synonyms: Morpholine,4-[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]- (9CI); Morpholine,4-[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]-, (E)-; TMK 848
• CAS NO: 100042-34-0
• Molecular Formula: C13H15 N O4
• Molecular Weight: 249.266
• Mol File: 100042-34-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-Propen-1-one,3-(3,4-dihydroxyphenyl)-1-(4-morpholinyl)-, (2E)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Propen-1-one,3-(3,4-dihydroxyphenyl)-1-(4-morpholinyl)-, (2E)-(100042-34-0)
• EPA Substance Registry System: 2-Propen-1-one,3-(3,4-dihydroxyphenyl)-1-(4-morpholinyl)-, (2E)-(100042-34-0)

Safety Data

• Hazardous Substances Data: 100042-34-0(Hazardous Substances Data)

Usage

Chemical group

3-(3,4-dihydroxyphenyl)-1-(4-morpholinyl)

Use

pharmaceutical intermediate

Potential therapeutic properties

studied for treatment of cancer and neurodegenerative disorders

Application

synthesis of other organic compounds in pharmaceutical and chemical industries

Upstream product

• 110-91-8 morpholine 
• 77201-71-9 (E)-3-(3,4-dihydroxyphenyl)acryloyl chloride 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 331-39-5 caffeic acid 

Downstream Products

• 22135-83-7 4-[3-(3,4-diacetoxy-phenyl)-acryloyl]-morpholine 

Relevant articles and documents

Discovery of a New Inhibitor of Myeloid Differentiation 2 from Cinnamamide Derivatives with Anti-Inflammatory Activity in Sepsis and Acute Lung Injury

Acute inflammatory diseases, including acute lung injury and sepsis, remain the most common life-threatening illness in intensive care units worldwide. Cinnamamide has been incorporated in several synthetic compounds with therapeutic potentials including anti-inflammatory properties. However, the possible mechanism and direct molecular target of cinnamamides for their anti-inflammatory effects were rarely investigated. In this study, we synthesized a series of cinnamamides and evaluated their anti-inflammatory activities. The most active compound, 2i, was found to block LPS-induced MD2/TLR4 pro-inflammatory signaling activation in vitro and to attenuate LPS-caused sepsis and acute lung injury in vivo. Mechanistically, we demonstrated that 2i exerts its anti-inflammatory effects by directly targeting and binding MD2 in Arg90 and Tyr102 residues and inhibiting MD2/TLR4 complex formation. Taken together, this work presents a novel MD2 inhibitor, 2i, which has the potential to be developed as a candidate for the treatment of sepsis, and provides a new lead structure for the development of anti-inflammatory agents targeting MD2.

ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES

The present invention relates to the use of caffeic acid or a derivative thereof represented by the following general formula (1 ) wherein X is O, NH, or heterocyclyl; R may be present or absent and if present, is H, alkyl, aryl, or heterocyclyl; in all its stereoisomeric and tautomeric forms, and mixtures thereof in all ratios, and a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable polymorph or a prodrug, in the treatment of chronic myeloid leukemia (CML) which is resistant to treatment with Gleevec. The invention also relates to a method for reducing the proliferation of cells that are resistant to Gleevec by contacting the cells with a compound of general formula (1 ). The present invention also relates to pharmaceutical compositions (for the manufacture of the medicament) including caffeic acid or a derivative or a salt thereof represented by the general formula (1 ) for the treatment of chronic myeloid leukemia (CML) that is resistant to treatment with Gleevec, or for reducing the proliferation of cells that are resistant to Gleevec. The present invention further relates to a method of treatment of chronic myeloid leukemia (CML) that is resistant to treatment with Gleevec.